Literature DB >> 28960327

Migraine and Yawning.

Bülent Güven1, Hayat Güven1, Selim Selçuk Çomoğlu1.   

Abstract

BACKGROUND: Yawning is considered to be a symptom that reflects dopaminergic activity, although its pathophysiological mechanism is not yet fully understood. Interestingly, repetitive yawning is seen in some patients during migraine attacks. The aim of this cross-sectional study is to investigate the frequency of yawning during migraine attacks and its association with different characteristics of migraine.
METHODS: Patients with migraine with or without aura were evaluated using questionnaires and diaries to determine the characteristics of headache and accompanying symptoms. Repetitive yawning in the premonitory phase and/or during headache were determined.
RESULTS: Three hundred and thirty-nine patients were included in the study. One hundred and fifty-four patients reported repetitive yawning (45.4%) during migraine attacks. Repetitive yawning was reported in the 11.2% of the patients in the premonitory phase, 24.2% during headaches, and 10% both in the premonitory phase and during headaches. Migraine with aura (46.8 vs 31.9%; P = .005), accompanying nausea (89.6 vs 75.1%; P = .001), vomiting (48.7 vs 37.8%; P = .044), osmophobia (66.7 vs 52.3%; P = .024), and cutaneous allodynia (58.2 vs 46%; P = .032) were more common in patients with yawning than without. Other dopaminergic-hypothalamic premonitory symptoms (41.6 vs 26.5%; P = .003), especially sleepiness (17.5 vs 5.9%; P = .001), irritability/anxiety (21.4% vs 11.4%; P = .019), nausea/vomiting (10.4 vs 4.3%; P = .03), and changes in appetite (18.2 vs 9.7%; P = .024), were also more frequent in patients with yawning than without. After being adjusted for all other relevant covariates, the odds of repetitive yawning were increased by the presence of nausea (OR 2.88; 95% CI 1.453-5.726; P = .002) and migraine with aura (OR 1.66; 95% CI 1.035-2.671; P = .036).
CONCLUSIONS: Our results demonstrated that yawning is a common self-reported symptom leading or accompanying migraine attacks and is associated with aura, nausea and/or vomiting, osmophobia, and cutaneous allodynia in patients with migraine. Although yawning is a rather frequently seen behavior, it is a unique and reliable symptom in patients with migraine that may offer an opportunity for early treatment of migraine attacks.
© 2017 American Headache Society.

Entities:  

Keywords:  dopamine; hypothalamus; migraine; yawning

Mesh:

Year:  2017        PMID: 28960327     DOI: 10.1111/head.13195

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  6 in total

1.  Hypothalamic regulation of headache and migraine.

Authors:  Arne May; Rami Burstein
Journal:  Cephalalgia       Date:  2019-08-29       Impact factor: 6.292

2.  Evidence for hyperprolactinemia in migraineurs: a systematic review and meta-analysis.

Authors:  Ali Noori-Zadeh; Morvarid Karamkhani; Ali Seidkhani-Nahal; Afra Khosravi; Shahram Darabi
Journal:  Neurol Sci       Date:  2019-08-23       Impact factor: 3.307

3.  Endogenous glucocorticoids may serve as biomarkers for migraine chronification.

Authors:  Yohannes W Woldeamanuel; Bharati M Sanjanwala; Robert P Cowan
Journal:  Ther Adv Chronic Dis       Date:  2020-07-21       Impact factor: 5.091

Review 4.  Caffeine and Primary (Migraine) Headaches-Friend or Foe?

Authors:  Karl B Alstadhaug; Anna P Andreou
Journal:  Front Neurol       Date:  2019-12-03       Impact factor: 4.003

5.  Exploring the neurobiology of the premonitory phase of migraine preclinically - a role for hypothalamic kappa opioid receptors?

Authors:  Caroline M Kopruszinski; Robson Vizin; Moe Watanabe; Ashley L Martinez; Luiz Henrique Moreira de Souza; David W Dodick; Frank Porreca; Edita Navratilova
Journal:  J Headache Pain       Date:  2022-09-30       Impact factor: 8.588

Review 6.  Imaging the Premonitory Phase of Migraine.

Authors:  Nazia Karsan; Peter J Goadsby
Journal:  Front Neurol       Date:  2020-03-25       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.